Navigation Links
Orion Pharma Selects ChemDiv as A Partner in Drug Discovery Services
Date:11/30/2007

SAN DIEGO, Nov. 30 /PRNewswire/ -- ChemDiv, Inc. and Orion Pharma today announced that Orion has chosen ChemDiv as a discovery partner in small molecule therapeutics for Orion's priority targets.

Under the terms of the agreement, ChemDiv will deploy the Discovery outSource(TM) platform for Orion's discovery program, including the world's largest commercially available chemical library, proprietary rational design, assay development, and bioscreening. ChemDiv will screen rationally designed chemical libraries against Orion's proprietary targets, and Orion will select hit series for subsequent lead optimization. Financial terms and identity of drug targets were not disclosed. The agreement provides options for expanding the discovery partnership.

"I am very satisfied with the commitment and exchange of information in our joint effort. We have a good basis for success," said Dr. Ari Koivisto, Orion's contact person in the collaboration. "Our partnership with ChemDiv complements our in-house discovery effort in this particular project," stated Dr. Antti Haapalinna, Director of Nonclinical R&D, Orion Pharma, Orion Corporation.

"We are delighted to offer discovery services to Orion Pharma in this partnership. We are especially pleased with the constructive dialog with Orion R&D, based on our mutual understanding and shared goals. Based on ChemDiv's diligence and track record, we are confident of success and look forward to expansion of this collaboration in the near future," commented Nikolay Savchuk, President and CEO of ChemDiv, Inc.

About Orion Corporation

Orion Corporation (OMX: ORNAV, ORNBV) is one of the leading pharmaceutical companies in the northern Europe. Orion develops, manufactures and markets pharmaceuticals, active pharmaceutical ingredients and diagnostic tests for global markets. Pharmaceuticals generate about 95% of the Group's net sales, of which proprietary patented pharmaceutical innovations contribute a considerable part. The core therapy areas in Orion's product and research strategy are central nervous system disorders, cardiology and critical care, urology and oncology. Stalevo(R) and Comtess(R) / Comtan(R), treatments originated by Orion for Parkinson 's disease, are the largest products by sales in Orion's portfolio. For additional information, please visit http://www.orion.fi.

About ChemDiv, Inc.

ChemDiv (http://www.chemdiv.com) is a global chemistry-driven contract research organization focused on identifying and delivering pre-clinical opportunities and advanced R&D services for the development of treatments for life-threatening diseases. For over 17 years, ChemDiv has provided its Discovery outSource(TM) solutions to life science partners, including medicinal and synthetic chemistry, pre-clinical development, screening libraries, and global logistics. ChemDiv's international research team encompasses 550 chemists and biologists in San Diego and Moscow based R&D centers.


'/>"/>
SOURCE ChemDiv, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Orion ICG, LLC Announces Acquisition of Cumberland Therapy Services, Inc.
2. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
3. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
9. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
10. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
11. Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... ... 24, 2016 , ... People across the U.S. are sharpening their pencils and ... essay contest in which patients and their families pay tribute to a genetic counselor ... National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
(Date:6/24/2016)... Maryland (PRWEB) , ... June 24, 2016 , ... ... Angels is actively feeding the Frederick area economy by obtaining investment capital for ... over the past 2½ years that have already resulted in more than a ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology: